BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Patrys Limited (PAB.AX) Raises $5.5 Million Following Closure Of Rights Issue


12/16/2013 8:33:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Melbourne, Australia; 16 December, 2013: Patrys Limited (ASX: PAB; Company) is pleased to confirm that it has raised $5,460,136 before costs from the Rights Issue and Share Top Up Offer that were announced on 13 November 2013. Combined with the Company’s existing cash reserves, Patrys now has over $10 million cash on hand.

Eligible Shareholders subscribed for 92,040,192 ordinary shares under the Rights Issue and 17,162,535 ordinary shares under the Share Top Up Offer.

These funds are sufficient to allow for the full cost of manufacturing of the GMP material for the investigator-sponsored trial (IST) which is being funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. This trial is evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with Onyx’s carfilzomib, in patients with relapsed and refractory multiple myeloma

In conjunction with Azure Capital Ltd and BBY Ltd as Joint Lead Managers to the Rights Issue, the Company will now seek to place the shortfall of 145,434,297 ordinary shares over the next three months in accordance with the ASX Listing Rules to select institutional and sophisticated investors.

“The Rights Issue was designed to allow our existing shareholders priority access to this fund raising. We are pleased with the support of our shareholders who participated in the Rights Issue.” said John Read, Patrys’ Chairman. “Importantly we have raised sufficient funds to enable us to manufacture the material required for the Onyx sponsored trial.”

The Company anticipates that the new shares will be entered into the holders’ security holdings on 19 December 2013 with trading of the new shares commencing on 20 December 2013.

For further information, please contact:

Dr. Marie Roskrow

Chief Executive Officer

P: +61 3 9670 3273

info@patrys.com

Patrys IR:

Rebecca Wilson

Buchan Consulting

P: 0417 382 391

rwilson@buchanwe.com.au

Patrys Media:

Shevaun Cooper

Buchan Consulting

P: +61 3 9866 4722

scooper@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that qualify for both internal development and partnering opportunities. More information can be found at www.patrys.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->